换一批
换一批Adalimumab dose escalation is effective and well tolerated in Crohn's disease patients with secondary loss of response to adalimumab.
作者：
主题词
成年人(Adult);消炎药(Anti-Inflammatory Agents);Crohn病(Crohn Disease);剂量效应关系, 药物(Dose-Response Relationship, Drug);药物耐受性(Drug Tolerance);女(雌)性(Female);法国(France);人类(Humans);Kaplan-Meiers评估(Kaplan-Meier Estimate);Logistic模型(Logistic Models);男(雄)性(Male);多元分析(Multivariate Analysis);缓解诱导(Remission Induction);回顾性研究(Retrospective Studies);时间因素(Time Factors);治疗结果(Treatment Outcome)
DOI
10.1016/j.dld.2016.11.002
PMID
27899263
发布时间
2022-04-08
- 浏览18
Digestive and liver disease
163-169页
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文
